Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.
Melanoma Manag
; 3(3): 177-186, 2016 Sep.
Article
em En
| MEDLINE
| ID: mdl-30190887
ABSTRACT
PURPOSE:
Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety.METHODS:
Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival.RESULTS:
We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI 3.1-12.2). Overall survival was 23.4 months (95% CI 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis.CONCLUSION:
SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article